New Oral Treatment May Help Migraines
Irish Company Allergan has entered into an agreement to acquire worldwide rights to Merck’s oral calcitonin gene-related peptide receptor antagonists, which are being tested in order to treat and prevent migraines. Allergan will get the rights for a payment of $250 million upfront, $125 million paid after HSR clearance, and $125 million paid next April. […]
Continue Reading